Home / Stocks / Glaxosmithkline Pharma Lt
GLAXO

Glaxosmithkline Pharma Lt Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹2,713.4

Change

+75.2 (2.85%)

Open

₹2,635.3

Prev. Close

₹2,638.2

Day High

₹2,719.9

Day Low

₹2,595.9

Volume Analysis

Traded

123,428

Delivered

67,726

Delivery %

54.87%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (45.6%)
  • •Strong operating margin (34.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (19.3%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,880.9 ₹2,800.4 ₹2,756.9 ₹2,676.4 ₹2,632.9 ₹2,552.4 ₹2,508.9
Fibonacci ₹2,800.4 ₹2,753.03 ₹2,723.77 ₹2,676.4 ₹2,629.03 ₹2,599.77 ₹2,552.4
Camarilla ₹2,747.5 ₹2,736.13 ₹2,724.77 ₹2,676.4 ₹2,702.03 ₹2,690.67 ₹2,679.3

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+10.48%

1 Week

+2.18%

1 Month

+10.1%

3 Months

-6.51%

6 Months

+17.62%

1 Year

+8.15%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹265.01

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

48.3%

Net margin 27.58% × asset turnover 0.83x × equity multiplier 2.11x

Company Overview

Sector

Healthcare

Market Cap

₹45,576 Cr

P/E (TTM)

40.2

ROE

45.6%

Book Value

₹111.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Glaxosmithkline Pharma Lt holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Valuation (14/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (45.6%); strong operating margin (34.0%). Strong 3-year EPS growth (19.3%).

TopFund Score — Fundamentals Quality

70/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

62

Valuation

14

Cash Flow

88

Corporate Governance

56

Momentum

58

Institutional Ownership

50

Business Quality

99

Risk & Volatility

69

Liquidity

89

From Screener.in

  • +Company is almost debt free.
  • +Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
  • +Company has been maintaining a healthy dividend payout of 94.6%
  • −Stock is trading at 24.1 times its book value
  • −The company has delivered a poor sales growth of 5.49% over past five years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Q2 FY27 earnings call: revenue up 21% to INR1,180 crore; EBITDA up 20%; Blenrep launch planned.

Video recording of analyst and institutional investor meetings uploaded on GSK investor website.

Recording of analyst and institutional investor meetings uploaded on GSK India investor website.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 957 805 930 815 1,011 949 974 805 980 1,041 995 938 1,184
Expenses + 668 587 673 584 689 658 641 554 644 670 644 643 782
Operating Profit 289 218 257 231 322 292 333 251 336 371 351 296 402
OPM % 30.0% 27.0% 28.0% 28.0% 32.0% 31.0% 34.0% 31.0% 34.0% 36.0% 35.0% 31.0% 34.0%
Other Income + 28 -135 32 36 39 35 41 44 36 50 36 44 73
Interest 0 0 1 0 0 0 1 0 1 1 1 1 0
Depreciation 18 17 18 16 17 19 15 16 17 20 13 16 15
Profit before tax 299 65 271 249 344 308 359 279 354 400 373 322 459
Tax % 27.0% 30.0% 28.0% 27.0% 27.0% 25.0% 27.0% 27.0% 27.0% 26.0% 26.0% 26.0% 27.0%
Net Profit + 218 46 194 182 252 230 263 205 257 296 278 237 336
EPS in Rs 13 3 11 11 15 14 16 12 15 17 16 14 20
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 4 0 18 7 6 18 5 -1 -3 10 2 17 21

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 15m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 3,305 2,838 2,908 2,871 3,128 3,224 2,926 3,278 3,252 3,454 3,749 3,822 4,159
Expenses + 2,672 2,360 2,489 2,363 2,527 2,567 2,327 2,516 2,447 2,545 2,570 2,512 2,739
Operating Profit 633 478 420 508 601 657 598 762 804 909 1,179 1,309 1,420
OPM % 19.0% 17.0% 14.0% 18.0% 19.0% 20.0% 20.0% 23.0% 25.0% 26.0% 31.0% 34.0% 34.0%
Other Income + 149 125 119 70 131 -262 9 1,401 103 -21 149 166 203
Interest 0 0 0 0 1 6 4 2 2 2 1 3 3
Depreciation 25 25 27 38 49 83 79 68 66 70 67 66 64
Profit before tax 756 578 511 540 683 306 525 2,093 839 816 1,260 1,406 1,555
Tax % 37.0% 35.0% 34.0% 35.0% 35.0% 70.0% 32.0% 19.0% 27.0% 28.0% 26.0% 26.0% —
Net Profit + 476 376 337 351 445 93 358 1,695 611 590 928 1,036 1,147
EPS in Rs 28 22 20 21 26 6 21 100 36 35 55 61 68
Dividend Payout % 111.0% 113.0% 75.0% 85.0% 76.0% 727.0% 142.0% 90.0% 89.0% 92.0% 99.0% 93.0% —
Sales growth 29 -14 2 -1 9 3 -9 12 -1 6 9 2 12

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 1,744 2,099 1,922 1,973 1,970 1,651 1,309 2,494 1,572 1,608 1,782 2,098 1,712
Borrowings + 3 2 2 1 1 0 35 20 16 19 10 33 39
Other Liabilities + 1,384 869 995 1,889 1,771 1,315 1,602 1,950 1,570 1,760 2,147 2,023 2,048
Total Liabilities 3,216 3,055 3,004 3,947 3,911 3,136 3,115 4,633 3,327 3,557 4,108 4,324 3,969
Fixed Assets + 123 204 258 325 432 758 387 331 330 321 284 281 293
CWIP 115 268 605 923 1,003 120 13 30 20 14 14 33 35
Investments 0 6 0 0 0 0 0 366 518 813 1,118 1,392 1,525
Other Assets + 2,977 2,577 2,140 2,700 2,477 2,257 2,715 3,907 2,458 2,408 2,692 2,618 2,116
Total Assets 3,216 3,055 3,004 3,947 3,911 3,136 3,115 4,633 3,327 3,557 4,108 4,324 3,969
Equity Capital 85 85 85 85 169 169 169 169 169 169 169 169 169

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 338 139 234 473 409 490 578 811 484 582 1,290 903
Cash from Investing Activity + 180 499 301 -104 -153 -57 418 -406 808 9 -46 397
Cash from Financing Activity + -497 -638 -511 -307 -358 -428 -696 -524 -1,543 -562 -769 -737
Net Cash Flow 21 0 24 62 -102 6 300 -119 -251 29 475 563
Free Cash Flow 175 -69 -24 639 166 336 536 2,371 451 573 1,273 870
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 93 72 94 133 101 103 121 122 93 92 116 93

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 75.0% → 75.0%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 13.42% 13.62% 13.48% 13.3% 13.21% 12.69% 12.41% 12.45% 12.67% 12.69% 12.42% 11.77%
Promoters 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0% 75.0%
Government 0.01% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FII 2.93% 3.48% 4.02% 4.36% 4.5% 4.52% 4.89% 4.79% 4.63% 4.62% 4.79% 4.75%
DII 8.64% 7.9% 7.51% 7.34% 7.3% 7.79% 7.71% 7.75% 7.7% 7.68% 7.81% 8.47%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Glaxosmithkline Pharma Lt (this stock) 45,576 40.2 24.22 45.6%
Ipca Laboratories Ltd 46,508 32.3 5.36 15.7%
Emcure Pharmaceuticals L 44,370 39.9 8.29 20.1%
Ajanta Pharma Limited 41,393 32.8 8.51 27.1%
Sai Life Sciences Limited 41,003 107.0 15.19 15.4%
Anthem Biosciences Ltd 51,355 81.4 15.65 22.3%
Global Health Limited 38,864 60.0 8.97 15.2%

Which Mutual Funds Hold Glaxosmithkline Pharma Lt?

Frequently Asked Questions about Glaxosmithkline Pharma Lt

Community Sentiment

What are other investors saying about Glaxosmithkline Pharma Lt?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.